Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins

Drug Metabolism and Disposition

Volumn 42, Issue 8, 2014, Pages 1301-1313

  Salphati, Laurent ^c   Chu, Xiaoyan ^f   Chen, Liangfu ^d   Prasad, Bhagwat ^g   Dallas, Shannon ^e   Evers, Raymond ^f   Mamaril Fishman, Donna ^d   Geier, Ethan G ^c   Kehler, Jonathan ^d   Kunta, Jeevan ^e   Mezler, Mario ^a   Laplanche, Loic ^a   Pang, Jodie ^c   Rode, Anja ⁱ   Soars, Matthew G ^b   Unadkat, Jashvant D ^g   Van Waterschoot, Robert A B ^a,j   Yabut, Jocelyn ^f   Schinkel, Alfred H ^h   Scheer, Nico ⁱ  

^a ABBVIE INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c GENENTECH INC   (United States)

^d GLAXOSMITHKLINE   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f MERCK RESEARCH LABORATORIES   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ TaconicArtemis   (Germany)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; FLUOROBENZENE; ORGANIC ANION TRANSPORTER; PYRIMIDINE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN; SLCO1B3 PROTEIN, HUMAN; SULFONAMIDE;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG METABOLISM; DRUG SCREENING; GENE; GENE EXPRESSION; LIQUID CHROMATOGRAPHY; LIVER CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SLC26A3 GENE; SLC30A10 GENE; SLC6A4 GENE; SLCO1B1 GENE; SLCO1B3 GENE; TANDEM MASS SPECTROMETRY; ANIMAL; DRUG INTERACTION; ENZYMOLOGY; GENETICS; HUMAN; LIVER; MALE; METABOLISM; PHYSIOLOGY;

ANIMALS; DRUG INTERACTIONS; FLUOROBENZENES; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MICE; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PRAVASTATIN; PYRIMIDINES; RNA, MESSENGER; SULFONAMIDES;

EID: 84904206778     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.057976     Document Type: Article

References (37)

1. Bi YA, Qiu X, Rotter CJ, Kimoto E, Piotrowski M, Varma MV, Ei-Kattan AF, and Lai Y (2013) Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharm Drug Dispos 34:452-461.
2. Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, Palm JE, Stieger B, and Evers R; International Transporter Consortium (2013) In vitro methods to support transporter evaluation in drug discovery and development. Clin Pharmacol Ther 94:95-112.
3. Chu X, Bleasby K, and Evers R (2013a) Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol 9:237-252.
4. Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, Green MD, Kuo Y, Liang Y, and Maciolek CM, et al. (2013b) In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 41:668-681.
5. Elsby R, Hilgendorf C, and Fenner K (2012) Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it' s not just about OATP1B1. Clin Pharmacol Ther 92:584-598.
6. Fujino H, Yamada I, Shimada S, and Kojima J (2002) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase - effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice. Drug Metab Pharmacokinet 17:449-456.
7. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
8. Gibaldi M and Perrier D (1982) Pharmacokinetics, Marcel Dekker, Inc., New York/Basel.
9. Grime K and Paine SW (2013) Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement. Drug Metab Dispos 41:372-378.
10. Hagenbuch B and Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1-18. (Pubitemid 36044060)
11. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665. (Pubitemid 38241451)
12. Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK, Smith PC, and Zamek-Gliszczynski MJ (2014) Utility of oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Drug Metab Dispos 42:182-192.
13. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68: 800-807. (Pubitemid 41206035)
14. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2006) Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229-1236.
15. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
16. Ieiri I, Higuchi S, and Sugiyama Y (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703-729.
17. Iusuf D, Ludwig M, Elbatsh A, van Esch A, van de Steeg E, Wagenaar E, van der Valk M, Lin F, van Tellingen O, and Schinkel AH (2014) OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice. Mol Cancer Ther 13:492-503.
18. Iusuf D, van Esch A, Hobbs M, Taylor M, Kenworthy KE, van de Steeg E, Wagenaar E, and Schinkel AH (2013) Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. Mol Pharmacol 83:919-929.
19. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
20. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
21. König J, Seithel A, Gradhand U, and Fromm MF (2006) Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 372:432-443.
22. Li WC, Ralphs KL, and Tosh D (2010) Isolation and culture of adult mouse hepatocytes. Methods Mol Biol 633:185-196.
23. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, and Collins R; SEARCH Collaborative Group (2008) SLCO1B1 variants and statin-induced myopathy- a genomewide study. N Engl J Med 359:789-799.
24. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, and Chiba K (2004) A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 19:453-455.
25. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
26. Peng SX, Rockafellow BA, Skedzielewski TM, Huebert ND, and Hageman W (2009) Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice. J Pharm Sci 98:1877-1884.
27. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
28. Prasad B, Evers R, Gupta A, Hop CE, Salphati L, Shukla S, Ambudkar S, and Unadkat JD (2013) Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos 42:78-88.
29. Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S, Houle R, and Chan G, et al. (2014) Pitavastatin is a more sensitive and selective OATP1B clinical probe than rosuvastatin. Br J Clin Pharmacol DOI: 10.1111/bcp.12377 [published ahead of print].
30. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, and Sugiyama Y (2013) Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34:45-78.
31. Takane H, Kawamoto K, Sasaki T, Moriki K, Moriki K, Kitano H, Higuchi S, Otsubo K, and Ieiri I (2009) Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol 63:1165-1169.
32. van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, and Kenworthy KE, et al. (2012) Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122:519-528.
33. van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, and Schinkel AH (2013) Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 19:821-832.
34. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, and Schinkel AH (2010) Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 120:2942-2952.
35. Williamson B, Soars AC, Owen A, White P, Riley RJ, and Soars MG (2013) Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA. Xenobiotica 43:920-931.
36. Yoshida K, Maeda K, and Sugiyama Y (2012) Transporter-mediated drug - drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther 91:1053-1064.
37. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, and Baker SD (2013) Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 19:1458-1466.